Haiyan Lei

Fujian Medical University — China

Medicine · Health Sciences

23h-index3.0kcitations351works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(86), PI3K/AKT/mTOR signaling in cancer(47), Protein Degradation and Inhibitors(47), Chronic Myeloid Leukemia Treatments(42), Cancer, Hypoxia, and Metabolism(36)

Publications351 total

Supplementary Data File S5 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Figure S3 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Figure S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Data File S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Data File S9 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Figure S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Data File S1 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
2025Open Access
Supplemental Figure S4 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
2025Open Access
Supplementary Data File S8 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplemental Figure S6 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
2025Open Access
Supplementary Figure S6 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Figure S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplemental Figure S3 from Inhibition of NAD<sup>+</sup>-Dependent Metabolic Processes Induces Cellular Necrosis and Tumor Regression in Rhabdomyosarcoma Models
2025Open Access
Supplementary Table S2 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Table S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Data File S2 from The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
2025Open Access
Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
2025Open Access
Supplementary Appendix S1 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
2025Open Access
page 1 of 18Next →

Frequent Co-authors

Jack F. Shern(17), Marielle E. Yohe(6), Brigitte C. Widemann(6), Xiyuan Zhang(6), Carol J. Thiele(5), Shien Tsai(5), Shao‐tao Tang(4), Aster H. Juan(4), Frank H. Ruddle(4), R. Taylor Sundby(4), Tianwei Li(4), Shyh‐Ching Lo(4), Zhouqin Feng(4), Jiaqing Shao(4), Haiying Qin(3), Javed Khan(3), Terry J. Fry(3), Markku Miettinen(3), Guoqing Cao(3), Arnulfo Mendoza(3)